Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

V. Dubruille · SciRah

Researcher profile · Semantic Scholar

V. Dubruille

Share profile

V. Dubruille — researcher profile on SciRah

h-index: 27
Works: 141
Citations: 3,047

Most-cited papers

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.
G. Étienne, J. Guilhot, D. Réa, F. Rigal-huguet +15 more
2017Journal of Clinical Oncology393 citations
Semantic Scholar
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
H. Kantarjian, T. Hughes, R. Larson, Dong-Wook Kim +17 more
2021Leukemia318 citations Open access
Semantic Scholar
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study
D. Réa, Guylaine Henry, Zena Khaznadar, G. Étienne +17 more
2017Haematologica152 citations Open access
Semantic Scholar
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients
F. Nicolini, S. Dulucq, L. Boureau, P. Cony-Makhoul +29 more
2019Clinical Cancer Research103 citations
Semantic Scholar
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group
D. Réa, S. Amé, M. Berger, J. Cayuela +16 more
2018Cancer75 citations Open access
Semantic Scholar
Preliminary Report Of The STIM2 Study: A Multicenter Stop Imatinib Trial For Chronic Phase Chronic Myeloid Leukemia De Novo Patients On Imatinib
F. Mahon, F. Nicolini, M. Noel, M. Escoffre +11 more
201362 citations
Semantic Scholar
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials
S. Verstovsek, R. Mesa, V MNSSVKR GUPTA, D. Lavie +16 more
2023Blood Advances52 citations Open access
Semantic Scholar
Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study.
F. Nicolini, G. Étienne, V. Dubruille, L. Roy +19 more
2015The Lancet Haematology49 citations
Semantic Scholar
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients
P. Rousselot, L. Mollica, J. Guilhot, A. Guerci +21 more
2021British Journal of Haematology47 citations Open access
Semantic Scholar
Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study.
A. Lassalle, P. Thomaré, C. Fronteau, B. Mahé +14 more
2016Annals of Oncology45 citations Open access
Semantic Scholar
Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.
M. Heiblig, D. Réa, M. Chrétien, A. Charbonnier +15 more
2018Experimental Hematology42 citations Open access
Semantic Scholar
Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center.
M. Loirat, P. Chevallier, C. Leux, A. Moreau +15 more
2015Annals of Oncology42 citations Open access
Semantic Scholar
Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life
C. Sortais, A. Lok, B. Tessoulin, T. Gastinne +14 more
2020Annals of Hematology40 citations
Semantic Scholar
Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study
M. Jullien, S. Trudel, B. Tessoulin, B. Mahé +14 more
2019Annals of Hematology32 citations
Semantic Scholar
Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation.
A. Clavert, Z. Perić, E. Brissot, F. Malard +12 more
2017Biology of Blood and Marrow Transplantation32 citations Open access
Semantic Scholar
Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients
P. Chevallier, M. Coste‐Burel, A. Le Bourgeois, P. Peterlin +15 more
2021eJHaem27 citations Open access
Semantic Scholar
Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy
T. Gastinne, A. Le Bourgeois, M. Coste‐Burel, T. Guillaume +16 more
2021British Journal of Haematology27 citations Open access
Semantic Scholar
Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis
T. Hughes, G. Saglio, R. Larson, H. Kantarjian +17 more
2019Blood27 citations Open access
Semantic Scholar
Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)
J. Kiladjian, J. Ianotto, J. Soret, N. Maslah +14 more
2022Blood25 citations Open access
Semantic Scholar
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial
F. Guilhot, Françoise Rigal-Huguet, J. Guilhot, A. Guerci-Bresler +51 more
2021Leukemia25 citations
Semantic Scholar
Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant
A. Le Bourgeois, M. Coste‐Burel, T. Guillaume, P. Peterlin +16 more
2021British Journal of Haematology25 citations Open access
Semantic Scholar
Escalated lymphodepletion followed by donor lymphocyte infusion can induce a graft-versus-host response without overwhelming toxicity
T. Guillaume, B. Gaugler, P. Chevallier, J. Delaunay +10 more
2012Bone Marrow Transplantation23 citations Open access
Semantic Scholar
Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
A. Le Bourgeois, C. Mohr, T. Guillaume, J. Delaunay +14 more
2013Biology of Blood and Marrow Transplantation21 citations Open access
Semantic Scholar
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial
S. Dulucq, F. Nicolini, D. Réa, P. Cony-Makhoul +26 more
2022Haematologica20 citations Open access
Semantic Scholar
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study
S. Trudel, B. Tessoulin, M. Jullien, N. Blin +13 more
2019Annals of Hematology19 citations
Semantic Scholar
Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.
P. Peterlin, J. Delaunay, T. Guillaume, T. Gastinne +10 more
2014Biology of Blood and Marrow Transplantation19 citations Open access
Semantic Scholar
Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced‐intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo‐SCT)
A. Le Bourgeois, Elsa Lestang, T. Guillaume, J. Delaunay +13 more
2013European Journal of Haematology18 citations
Semantic Scholar
Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies
P. Chevallier, P. Peterlin, A. Garnier, A. Le Bourgeois +11 more
2018OncoTarget17 citations Open access
Semantic Scholar
A new cytokine‐based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia
P. Peterlin, J. Gaschet, T. Guillaume, A. Garnier +19 more
2020Cancer Medicine15 citations Open access
Semantic Scholar
Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients
S. Verstovsek, M. Egyed, E. Lech-Maranda, T. Sacha +15 more
202015 citations Open access
Semantic Scholar
Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial
F. Nicolini, G. Étienne, F. Huguet, A. Guerci-Bresler +25 more
2021Blood14 citations
Semantic Scholar
FLT3 ligand plasma levels in acute myeloid leukemia
P. Peterlin, J. Gaschet, T. Guillaume, A. Garnier +20 more
2019Haematologica14 citations Open access
Semantic Scholar
Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma
C. Touzeau, N. Blin, A. Clavert, V. Roland +11 more
2012Leukemia and Lymphoma14 citations
Semantic Scholar
Is ASCT With TBI Superior to ASCT Without TBI in Mantle Cell Lymphoma Patients?
P. Peterlin, C. Leux, T. Gastinne, V. Roland +16 more
2012Transplantation14 citations Open access
Semantic Scholar
Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/−R) is an effective treatment with low toxicity in Hodgkin’s and non-Hodgkin’s lymphomas
B. Tessoulin, P. Thomare, E. Delande, J. Moynard +17 more
2017Annals of Hematology13 citations
Semantic Scholar
Safety and efficacy of rituximab in steroid-refractory chronic GVHD
A. Clavert, P. Chevallier, T. Guillaume, J. Delaunay +7 more
2013Bone Marrow Transplantation13 citations
Semantic Scholar
Dasatinib plus Peg‐Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA‐PegIFN study)
L. Roy, J. Chomel, J. Guilhot, A. Guerci-Bresler +23 more
2022British Journal of Haematology12 citations
Semantic Scholar
Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience
V. Laurent, C. Fronteau, C. Antier, P. Dupuis +21 more
2020Bone Marrow Transplantation12 citations
Semantic Scholar
The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.
F. Nicolini, G. Étienne, F. Huguet, A. Guerci-Bresler +28 more
2019Blood12 citations Open access
Semantic Scholar
Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)
L. Roy, J. Chomel, J. Guilhot, A. Guerci-Bresler +26 more
201512 citations
Semantic Scholar
Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience
J. Bourcier, T. Gastinne, C. Leux, A. Moreau +16 more
2016Annals of Hematology11 citations
Semantic Scholar
Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study
Sophie Vantyghem, P. Peterlin, S. Thepot, A. Menard +33 more
2020Haematologica10 citations Open access
Semantic Scholar
Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma
E. Brissot, A. Clavert, N. Blin, V. Roland +8 more
2015Leukemia8 citations
Semantic Scholar
Phase I study of zoledronic acid combined with escalated doses of interleukine‐2 for early in vivo generation of Vγ9Vδ2 T‐cells after haploidentical stem cell transplant with posttransplant cyclophosphamide
M. Jullien, T. Guillaume, A. Le Bourgeois, P. Peterlin +18 more
2024American journal of hematology/oncology7 citations Open access
Semantic Scholar
Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide
A. Garnier, T. Guillaume, P. Peterlin, A. Le Bourgeois +13 more
2020Annals of Hematology7 citations
Semantic Scholar
Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial
F. Nicolini, G. Étienne, F. Huguet, A. Guerci-Bresler +27 more
20177 citations
Semantic Scholar
Pegylated Interferon-α 2a in Combination to Nilotinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Provides High Rates of MR4.5. Preliminary Results of a Phase II Study.
F. Nicolini, G. Étienne, V. Dubruille, L. Roy +19 more
20127 citations
Semantic Scholar
Preemptive Immunoglobulin Prophylaxis Reduces Infections in Patients Treated With Anti-BCMA Bispecific Antibodies.
Bénédicte Piron, L. Rodrigo, B. Tessoulin, T. Gastinne +8 more
2025Clinical Lymphoma, Myeloma & Leukemia6 citations Open access
Semantic Scholar
Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
H. Kantarjian, T. Hughes, R. Larson, Dong-Wook Kim +17 more
2021Leukemia6 citations Open access
Semantic Scholar
RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation
Baptiste Le Calvez, Yannick Le Bris, Guillaume Herbreteau, B. Jamet +13 more
2020eJHaem6 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

B. Mahé×26
Invite
B. Mahé — researcher profile on SciRah
N. Blin×26
Invite
N. Blin — researcher profile on SciRah
T. Gastinne×25
Invite
T. Gastinne — researcher profile on SciRah
S. le Gouill×25
Invite
S. le Gouill — researcher profile on SciRah

×24

Invite

T. Guillaume — researcher profile on SciRah

Invite

P. Moreau — researcher profile on SciRah

G. Étienne×19

Invite

G. Étienne — researcher profile on SciRah

P. Peterlin×19

Invite

P. Peterlin — researcher profile on SciRah

Invite

C. Touzeau — researcher profile on SciRah

P. Chevallier×17

Invite

P. Chevallier — researcher profile on SciRah

Invite

D. Réa — researcher profile on SciRah

P. Rousselot×16

Invite

P. Rousselot — researcher profile on SciRah